Coptisine mitigates diabetic nephropathy via repressing the NRLP3 inflammasome

Abstract Diabetic nephropathy is a microvascular complication of diabetes mellitus, threatening the health of millions of people. Herein, we explored a blood glucose independent function of coptisine on diabetic nephropathy. A diabetic rat model was established by intraperitoneal administration of streptozotocin (65 mg/kg). Coptisine treatment (50 mg/kg/day) retarded body weight loss and reduced blood glucose. On the other hand, coptisine treatment also decreased kidney weight and the levels of urinary albumin, serum creatinine, and blood urea nitrogen, indicating an improvement of renal function. Treatment with coptisine also mitigated renal fibrosis, with alleviative collagen deposition. Likewise, in vitro study showed that coptisine treatment decreased apoptosis and fibrosis markers in HK-2 cells treated with high glucose. Furthermore, after coptisine treatment, the activation of NOD-like receptor pyrin domain containing protein 3 (NRLP3) inflammasome was repressed, with decreased levels of NLRP3, cleaved caspase-1, interleukin (IL)-1β, and IL-18, indicating that the repression of NRLP3 inflammasome contributed to the effect of coptisine on diabetic nephropathy. In conclusion, this study revealed that coptisine mitigates diabetic nephropathy via repressing the NRLP3 inflammasome. It is indicated that coptisine may have the potential to be used in the diabetic nephropathy treatment.

[1]  Yitao Wang,et al.  Coptisine Attenuates Diabetes—Associated Endothelial Dysfunction through Inhibition of Endoplasmic Reticulum Stress and Oxidative Stress , 2021, Molecules.

[2]  W. Ding,et al.  NLRP3 Deletion Attenuated Angiotensin II-Induced Renal Fibrosis by Improving Mitochondrial Dysfunction and Endoplasmic Reticulum Stress , 2021, Nephron.

[3]  Yifu Yang,et al.  Coptisine induces G2/M arrest in esophageal cancer cell via the inhibition of p38/ERK1/2/claudin-2 signaling pathway. , 2021, Pharmazie.

[4]  Jiawei Chen,et al.  Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2/STAT3/SOCS1 pathway in streptozotocin-induced diabetic rats. , 2020, Life sciences.

[5]  Yung-Hyun Choi,et al.  Inhibition of oxidative stress induced-cytotoxicity by coptisine in V79-4 Chinese hamster lung fibroblasts through the induction of Nrf-2 mediated HO-1 expression , 2020, Genes & Genomics.

[6]  Pengfei Wang,et al.  Coptisine alleviates ischemia/reperfusion-induced myocardial damage by regulating apoptosis-related proteins. , 2020, Tissue & cell.

[7]  U. Murty,et al.  Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches. , 2020, European journal of pharmacology.

[8]  Jian Gao,et al.  Coptisine suppresses proliferation and inhibits metastasis in human pancreatic cancer PANC-1 cells , 2020, Journal of Asian natural products research.

[9]  P. Li,et al.  Inhibition of Nrf2/HO-1 signaling leads to increased activation of the NLRP3 inflammasome in osteoarthritis , 2019, Arthritis Research & Therapy.

[10]  H. Lan,et al.  Deletion of Smad3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy. , 2019, Metabolism: clinical and experimental.

[11]  Z. Ni,et al.  NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation. , 2019, Experimental cell research.

[12]  L. Fang,et al.  Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice. , 2019, European journal of pharmacology.

[13]  Xiaoxia Lu,et al.  Coptisine from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting caspase-1. , 2019, Pharmacological research.

[14]  Zhengquan Ma,et al.  Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway , 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

[15]  R. Nishimura,et al.  Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease , 2019, International journal of molecular sciences.

[16]  H. Duan,et al.  NLRP3 deficiency ameliorates renal inflammation and fibrosis in diabetic mice , 2018, Molecular and Cellular Endocrinology.

[17]  Jianhui Xie,et al.  Anti-inflammatory activity of coptisine free base in mice through inhibition of NF-κB and MAPK signaling pathways. , 2017, European journal of pharmacology.

[18]  Ming Gu,et al.  Coptisine protects cardiomyocyte against hypoxia/reoxygenation-induced damage via inhibition of autophagy. , 2017, Biochemical and biophysical research communications.

[19]  H. Florez,et al.  How to prevent the microvascular complications of type 2 diabetes beyond glucose control , 2017, British Medical Journal.

[20]  M. Du,et al.  [Determination of six alkaloids in six types of Coptidis Rhizoma pieces by RP-HPLC and spectrum-effect relationships with anti-diabetes pharmacodynamics data]. , 2016, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.

[21]  Li Hu,et al.  Coptisine Prevented IL-β-Induced Expression of Inflammatory Mediators in Chondrocytes , 2016, Inflammation.

[22]  C. Sasakawa,et al.  Molecular mechanisms regulating NLRP3 inflammasome activation , 2015, Cellular and Molecular Immunology.

[23]  K. Reymann,et al.  Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy , 2014, Kidney international.

[24]  Richard A. Flavell,et al.  Inflammasomes in health and disease , 2012, Nature.

[25]  W. T. Cade,et al.  Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting , 2008, Physical Therapy.

[26]  Lin Sun,et al.  A Glimpse of the Mechanisms Related to Renal Fibrosis in Diabetic Nephropathy. , 2019, Advances in experimental medicine and biology.

[27]  Maria João Pires,et al.  Pathophysiological Mechanisms of Renal Fibrosis: A Review of Animal Models and Therapeutic Strategies. , 2017, In vivo.

[28]  S. Tang,et al.  Current practices in the management of diabetic nephropathy. , 2013, The journal of the Royal College of Physicians of Edinburgh.